metastatic prostate cancer
Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues
Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues
Bayer’s Kerendia granted FDA approval for new heart failure indication
Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%
GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
The decision means that eligible patients in England will be the first in the world to access the combination
Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours
The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway
NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis
Around 1,000 patients could benefit from the relugolix combination therapy every year
Amgen’s Blincyto recommended by NICE for new adult leukaemia indication
Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment
FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate
The progressive neurodegenerative disease affects more than ten million people worldwide
Bayer UK launches digital educational hub to improve menopause support
An estimated 13 million women in the UK are currently perimenopausal or menopausal
AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi
More than 49,000 people are diagnosed with lung cancer in the UK each year
Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial
Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy
NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree
Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision
NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer
More than 100 patients are expected to be eligible for the treatment every year